Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, Nizar Jacques Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Yair Levy, Michael H Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P Chu, Cristina J. Gasparetto, Andrew P. Dalovisio, Michael Sebag, Alexander M Lesokhin

Blood (2022) 140 (Supplement 1): 388–390.

https://doi.org/10.1182/blood-2022-166494

Published: 2022

Journal Articles

Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib

Ryan Jacobs, Xiaoxiao Lu, Bruno Emond, Laura Morrison, Frédéric Kinkead, Patrick Lefebvre, Marie-Hélène Lafeuille, Wasiulla Khan, Linda Wu, Zaina P. Qureshi, Moshe Yair Levy

Blood (2022) 140 (Supplement 1): 1931–1933.

https://doi.org/10.1182/blood-2022-163387

Published: 2022

Journal Articles

Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib

Ryan Jacobs, Ruibin Wang, Jinghua He, Xiaoxiao Lu, Linda Wu, Wasiulla Khan, Zaina P. Qureshi, Moshe Yair Levy

Blood (2022) 140 (Supplement 1): 8017–8018.

https://doi.org/10.1182/blood-2022-168081

Published: 2022

Journal Articles

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Edwin C. Kingsley, Benjamin Freeman, Moshe Yair Levy, Houston Holmes, Charles M. Farber, Arvind Chaudhry, Rocco Crescenzo, Adam Idoine, Xiaoping Zhang, Aileen Cohen, Kunthel By, Jane Huang, Jeff P. Sharman

Blood (2022) 140 (Supplement 1): 3655–3657.

https://doi.org/10.1182/blood-2022-159726

Published: 2022

Journal Articles

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Koji Sasaki, Michael Mauro, Moshe Yair Levy, Ehab L. Atallah, Paul B. Koller, Rodrigo Maegawa, Andrea Damon, Julie Kumar, Mahmudul Khan, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 6784–6786.

https://doi.org/10.1182/blood-2022-167044

Published: 2022

Journal Articles

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 9269–9271.

https://doi.org/10.1182/blood-2022-167758

Published: 2022

Journal Articles

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

Moshe Yair Levy, MD, Lin Xie, MA, MS, Yuexi Wang, Frank Neumann, MD PhD, Shouryadeep Srivastava, MBBS, PhD, Daniel Naranjo, Jing Xu, Qisu Zhang, MPH, Mehul Dalal, PhD

Blood (2019) 134 (Supplement_1): 4751.

https://doi.org/10.1182/blood-2019-129053

Published: 2019

Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Blood (2019) 134 (Supplement_1): 5642.

https://doi.org/10.1182/blood-2019-122776

Published: 2019

Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Tara L Lin, MD, Carlos E Vigil, MD, Andrew Dalovisio, MD, Eunice S. Wang, MD, Moshe Yair Levy, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD, Pau Montesinos, MD PhD, Juan Miguel Miguel Bergua Burgues, Jeffrey R. Schriber, MD, Stephen Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD

Blood (2018) 132 (Supplement 1): 30.

https://doi.org/10.1182/blood-2018-99-115018

Published: 2018

Journal Articles

Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia

Moshe Yair Levy, MD, Lin Xie, MA, MS, Yuexi Wang, Frank Neumann, MD PhD, Shouryadeep Srivastava, MBBS, PhD, Daniel Naranjo, Qisu Zhang, Mehul Dalal, PhD

Blood (2018) 132 (Supplement 1): 3567.

https://doi.org/10.1182/blood-2018-99-113490

Published: 2018

Journal Articles

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, MD PhD, Antonio Jiménez-Velasco, MD, Sarah Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Yair Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin Regueira, MD, Jeffrey H. Lipton, MD PhD

Blood (2018) 132 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2018-99-116563

Published: 2018

Journal Articles

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Edward Agura, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Mark R. Litzow, MD, Benjamin K. Tomlinson, MD, Sunil Abhyankar, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Hannah K. Choe, MD, Partow Kebriaei, MD, James M. Foran, MD, George Chen, MD, Moshe Yair Levy, MD, Hillard M Lazarus, MD, Sergio Giralt, MD, Mark S. Berger, MD, Vijay Reddy, MD PhD, John M. Pagel, MD PhD

Blood (2018) 132 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2018-99-111914

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Ehab L. Atallah, MD, Johnnie J. Orozco, MD PhD, Michael Craig, MD, Moshe Yair Levy, MD, Laura E. Finn, MD, Sharif S. Khan, MD, Alexander E. Perl, MD, Jae H. Park, MD, Gail J. Roboz, MD, William Tse, MD, Kebede H. Begna, MD, Raya Mawad, MD, David A. Rizzieri, MD, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2018) 132 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2018-99-111951

Published: 2018

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Moshe Yair Levy, MD, Jae H. Park, MD, Farhad Ravandi, MD, Alexander E. Perl, MD, John M. Pagel, MD PhD, B. Douglas Smith, MD, Elihu H. Estey, MD, Hagop Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4050.

https://doi.org/10.1182/blood.V128.22.4050.4050

Published: 2016

Journal Articles

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Blood (2016) 128 (22): 104.

https://doi.org/10.1182/blood.V128.22.104.104

Published: 2016

Journal Articles

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Previously Treated Myeloma

Vincent L Hansen, MD, Morton Coleman, MD, Stephanie Elkins, MD, Jeffrey P. Letzer, Moshe Yair Levy, MD, Lasika Seneviratne, MD, Jessica Rine, Marina White, Emil T Kuriakose, MD

Blood (2015) 126 (23): 3027.

https://doi.org/10.1182/blood.V126.23.3027.3027

Published: 2015

Journal Articles

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H. Park, MD, B. Douglas Smith, MD, Moshe Yair Levy, MD, Elihu H. Estey, MD, Alexander E. Perl, MD, Hagop Kantarjian, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2015) 126 (23): 3794.

https://doi.org/10.1182/blood.V126.23.3794.3794

Published: 2015

Journal Articles

Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

Moshe Yair Levy, MD, Lisa J. McGarry, MPH, Stephanie Lustgarten, PhD, Mo Yang, PhD, Frank G. Haluska, MD

Blood (2015) 126 (23): 1588.

https://doi.org/10.1182/blood.V126.23.1588.1588

Published: 2015

Journal Articles

Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

Moshe Yair Levy, MD, Lisa J McGarry, MPH, Hui Huang, PhD MBA, Stephanie Lustgarten, PhD, Christopher Nieset, PharmD, Frank G Haluska

Blood (2014) 124 (21): 3154.

https://doi.org/10.1182/blood.V124.21.3154.3154

Published: 2014

NARROW

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib

Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Previously Treated Myeloma

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only